Germany's Bayer Pharmaceutical Corp and USA-based Onyx Pharmaceuticals have completed patient enrollment in two randomized, double-blind, Phase III clinical trials of their co-developed anticancer drug Nexavar (sorafenib). in one of the evaulations, the oral multikinase inhibitor will be administered as tablets in combination with carboplatin and paclitaxel in patients with advanced metastatic melanoma and in the other, it will be given as a single agent in patients with advanced hepatocellular carcinoma (HCC), or liver cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze